Factors associated with peripheral neuropathy in type 2 diabetes: Subclinical versus confirmed neuropathy

Abstract

This study determined the prevalence of diabetic peripheral neuropathy (DPN) and subclinical DPN (sDPN) in patients with type 2 diabetes mellitus (T2DM) using nerve conduction study (NCS) as a diagnostic tool. We also investigated the factors associated with the development of sDPN and compared factors between the sDPN and confirmed DPN (cDPN). This cross-sectional study involved 240 T2DM patients who were successively admitted to the endocrinology wards of Wuhan Union Hospital over the period of January to December 2014. Data on the medical history, physical and laboratory examinations were collected. DPN was diagnosed using NCS. One-way ANOVA with least significant difference (LSD) analysis or chi-square tests was used to compare parameters among DNP-free, sDPN and cDPN patients. Independent factors associated with sDPN were determined using logistic regression. The results showed that 50.8% of the participants had DPN, and among them, 17.1% had sDPN. sDPN showed significant independent associations with age, height, HbA1c, presence of atherosclerosis and diabetic retinopathy. Patients with DPN differed significantly from those without DPN with respect to age, duration of disease (DOD), HbA1c, presence of atherosclerosis, diabetic retinopathy, nephropathy and hypertension. Patients with cDPN, relative to those with sDPN, had significantly longer DOD and higher prevalence of peripheral artery disease (PAD) and coronary artery disease (CAD). Our study suggests that a significant number of T2DM patients are affected by sDPN, and the development of this condition is associated with advanced age, tall stature, poor glycaemic control, presence of diabetic retinopathy and atherosclerosis. On the other hand, patients with cDPN tend to have a longer DOD and are more likely to suffer from PAD and CAD.

Keywords

diabetic peripheral neuropathy / type 2 diabetes mellitus / subclinical diabetic peripheral neuropathy / nerve conduction study

References

[1] VinikA, UllalJ, ParsonHK, et al. . Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab, 2006, 2(5): 269-281 PMID: 16932298

[2] SmithSC, LampingDL, MaclaineGD. Measuring healthrelated quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract, 2012, 96(3): 261-270 PMID: 22154463

[3] GalerBS, GianasA, JensenMP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract, 2000, 47(2): 123-128 PMID: 10670912

[4] WangA, XuZ, MuY, et al. . Clinical characteristics and medical costs in patients with diabetic amputation and nondiabetic patients with nonacute amputation in central urban hospitals in China. Int J Low Extrem Wounds, 2014, 13(1): 17-21 PMID: 24659623

[5] OlaleyeD, PerkinsBA, BrilV. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract, 2001, 54(2): 115-128 PMID: 11640995

[6] DyckPJ, AlbersJW, AndersenH, et al. . Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev, 2011, 27(7): 620-628 PMID: 21695763

[7] VinikAI, KongX, MegerianJT, et al. . Diabetic nerve conduction abnormalities in the primary care setting. Diabetes Technol Ther, 2006, 8(6): 654-662 PMID: 17109597

[8] PerkinsBA, OlaleyeD, ZinmanB, et al. . Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care, 2001, 24(2): 250-256 PMID: 11213874

[9] HussainG, RizviSA, SinghalS, et al. . Cross sectional study to evaluate the of duration of type 2 diabetes mellitus on the nerve conduction velocity in diabetic peripheral neuropathy. Diabetes Metab Syndr, 2014, 8(1): 48-52 PMID: 24661759

[10] Meijer JW, Smit AJ, Lefrandt JD, et al. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care, 2005,28(9):2201–2205

[11] ValensiP, AttaliJR, GagantS. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. Diabet Med, 1993, 10(10): 933-939

[12] BoultonAJM, MalikRA, ArezzoJC, et al. . Diabetic somatic neuropathies. Diabetes Care, 2004, 27(6): 1458-1486 PMID: 15161806

[13] MeijerJW, BosmaE, LefrandtJD, et al. . Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care, 2003, 26(3): 697-701 PMID: 12610024

[14] BoultonAJM, VinikAI, ArezzoJC, et al. . Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care, 2005, 28(4): 956-962 PMID: 15793206

[15] DyckPJ, OverlandCJ, LowPA, et al. . Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve, 2010, 42(2): 157-164 PMID: 20658599

[16] BertoraP, VallaP, DezuanniE, et al. . Prevalence of subclinical neuropathy in diabetic patients: assessment by study of conduction velocity distribution within motor and sensory nerve fibres. J Neurol, 1998, 245(2): 81-86 PMID: 9507412

[17] AkbarDH, MiraSA, ZawawiTH, et al. . Subclinical diabetic neuropathy: a common complication in Saudi diabetics. Saudi Med J, 2000, 21(5): 433-437 PMID: 11500676

[18] PopescuS, TimarB B, et al. . Age as an independent factor for the development of neuropathy in diabetic patients. Clin Interv Aging, 2016, 11: 313-318 PMID: 27042031 PMCID: 4801151

[19] PapanasN, ZieglerD. Risk factors and comorbidities in diabetic neuropathy: An update 2015. Rev Diabet Stud, 2015, 12(1–2): 48-62 PMID: 26676661

[20] AdlerAI, BoykoEJ, AhroniJH, et al. . Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care, 1997, 20(7): 1162-1167 PMID: 9203456

[21] TesfayeS, StevensLK, StephensonJM, et al. . Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia, 1996, 39(11): 1377-1384 PMID: 8933008

[22] ShawJE, HodgeA d, CourtenM, et al. . Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract, 1998, 42(2): 131-139 PMID: 9886750

[23] Cabezas-CerratoJ. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia, 1998, 41(11): 1263-1269

[24] YoungMJ, BoultonAJ, MacLeodAF, et al. . A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia, 1993, 36(2): 150-154 PMID: 8458529

[25] BansalD, GudalaK, MuthyalaH, et al. . Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig, 2014, 5(6): 714-721 PMID: 25422773 PMCID: 4234236

[26] ErbasT, ErtasM, YucelA, et al. . Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients. J Clin Neurophysiol, 2011, 28(1): 51-55 PMID: 21221008

[27] LuB, YangZ, WangM, et al. . High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract, 2010, 88(3): 289-294 PMID: 20359765

[28] The Diabetes ControlComplications Trial Research Group.. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med, 1995, 122(8): 561-568

[29] DuckworthW, AbrairaC, MoritzT, et al. . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360(2): 129-139 PMID: 19092145

[30] Ismail-BeigiF, CravenT, BanerjiMA, et al. . Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, 2010, 376(9739): 419-430 PMID: 20594588 PMCID: 4123233

[31] HolmanRR, PaulSK, BethelMA, et al. . 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359(15): 1577-1589 PMID: 18784090

[32] ZieglerD, RathmannW, DickhausT, et al. . Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care, 2008, 31(3): 464-469 PMID: 18039804

[33] Ybarra-MunozJ, Jurado-CamposJ, Garcia-GilM, et al. . Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study. Eur J Cardiovasc Nurs, 2016, 15(4): 248-254 PMID: 25527522

[34] TesfayeS, ChaturvediN, EatonSEM, et al. . Vascular risk factors and diabetic neuropathy. N Engl J Med, 2005, 352(4): 341-350 PMID: 15673800

[35] MorkridK, AliL, HussainA. Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh. Int J Diabetes Dev Ctries, 2010, 30(1): 11-17 PMID: 20431800 PMCID: 2859278

[36] KatulandaP, RanasingheP, JayawardenaR, et al. . The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr, 2012, 4(1): 21 PMID: 22642973 PMCID: 3408375

[37] LuB, HuJ, WenJ, et al. . Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-diabetes -ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SH-DREAMS). PLoS One, 2013, 8(4): e61053 PMID: 23613782 PMCID: 3628856